Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 16/20 | 0.71 |
| ▸ | F11 | P03951 | 4/20 | 0.44 |
| ▸ | TPSB2 | P20231 | 4/20 | 0.44 |
| ▸ | PLAU | P00749 | 2/20 | 0.44 |
| ▸ | PLG | P00747 | 1/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.44 |
| ▸ | F7 | P08709 | 1/20 | 0.44 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.37 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.34 |
| ▸ | SELL | P14151 | 1/20 | 0.34 |
| ▸ | SELP | P16109 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25879818 | 0.90 | CFD (0.64) | CFDF11TPSB2PLAUPLG | |
| SCHEMBL21439523 | 0.85 | CFD (0.71) | CFDF11TPSB2SUCNR1 | |
| SCHEMBL31090071 | 0.85 | CFD (0.71) | CFDF11TPSB2SUCNR1 | |
| SCHEMBL25879822 | 0.78 | CFD (0.48) | CFDSUCNR1 | |
| SCHEMBL21437981 | 0.77 | CFD (0.63) | CFDF11TPSB2SUCNR1 | |
| SCHEMBL31266585 | 0.69 | CFD (0.69) | CFDSUCNR1 | |
| SCHEMBL21455667 | 0.69 | CFD (0.69) | CFDSUCNR1 | |
| SCHEMBL21439457 | 0.69 | CFD (0.56) | CFD | |
| SCHEMBL25879855 | 0.67 | CFD (0.72) | CFDF11TPSB2PLAUPLG | |
| SCHEMBL21438222 | 0.66 | CFD (0.80) | CFDF11TPSB2PLAUPLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | CFD 17/4885F11 216/4885TPSB2 169/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.